Valerie Cullen, PhD

Dr. Valerie Cullen is Senior Vice President, Research and Translational Science at Lysoway Therapeutics. Previously, she was SVP, Head of Research at Expansion Therapeutics, responsible for multiple programs targeting RNA biology in neurodegenerative and neuromuscular disease. As Vice President and Program Lead at Lysosomal Therapeutics, Inc (LTI), she led the GCase program from discovery into clinical testing in Parkinson’s Disease, with particular oversight of the Translational Medicine function. Earlier in her career, she conducted drug discovery research for multiple neurodegenerative diseases at Generian Pharmaceuticals, Aldeyra Theraeputics, NeuroPhage Pharmaceuticals and Link Medicine. She has directly contributed to numerous regulatory filings in Europe and the US. Dr. Cullen earned her PhD and BSc (Hons) in Pharmacology at University College Dublin, Ireland and completed research fellowships in Neuroscience at King’s College, London and Harvard Medical School. She has been awarded the Zeneca Prize and the Annals of Neurology Prize for Highest Clinical Impact.